查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447590

肝病诊断市场规模- 按疾病类型（肝炎、肝硬化、肝癌、非酒精性脂肪肝病(NAFLD)）、技术（影像、肝臟活检、内视镜检查、实验室测试）、最终用途- 全球预测（2024 年 -第2032章

Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在技​​术进步、肝病盛行率上升以及早期诊断意识提高的推动下，全球肝病诊断市场预计在 2024 年至 2032 年期间CAGR为 7.3%。

据世界卫生组织称，全球有 3.54 亿人受到B型或丙型肝炎感染。久坐的生活方式、不健康的饮食习惯和饮酒盛行等因素导致肝臟疾病的增加，从而增加了对先进诊断解决方案的需求。此外，人口老化，特别是在已开发地区，更容易患肝臟相关疾病。此外，强调早期发现和介入以预防严重併发症正在促进肝病诊断测试和程序的采用。

整个肝病诊断行业根据疾病类型、技术、最终用途和地区进行分类。

由于死亡率高和治疗选择有限，特别是在晚期，肝癌细分市场预计到 2032 年将大幅成长。因此，迫切需要准确、及时地诊断肝癌。有多种诊断方式，例如影像技术（CT 扫描、MRI）、血液检查（AFP、AFP-L3）和活检程序。影像技术和生物标记识别的不断进步也提高了肝癌诊断的精确度和可靠性，进一步推动了产业的成长。

内视镜技术领域预计到 2032 年将迅速扩展，提供直接视觉化和组织采样功能。内视镜成像技术的发展，包括高清示波器和先进的成像模式，如窄带成像(NBI) 和共焦雷射内视镜(CLE)，透过提供对组织形态和血管分布的详细了解，正在彻底改变肝臟疾病的诊断，推动细分市场的发展与成长。

由于肝病的高盛行率、完善的医疗基础设施以及旨在降低肝臟相关发病率和死亡率的积极政府倡议等因素，欧洲肝病诊断市场在预测期内将拥有利润丰厚的机会。专注于肝臟健康的主要参与者和研究机构的存在进一步增强了该地区的成长前景。此外，老年人口的增加以及对早期诊断重要性的认识不断提高，正在推动整个欧洲对肝病诊断测试和程序的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 肝臟疾病盛行率增加
      • 吸烟、酗酒和吸毒的人数增加
      • 诊断试剂盒的技术进步
    • 产业陷阱与挑战
      • 诊断测试成本高
  • 成长潜力分析
  • 监管环境
  • 报销场景
  • 未来市场趋势
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疾病类型，2018 - 2032

  • 主要趋势
  • 肝炎
  • 肝硬化
  • 肝癌
  • 非酒精性脂肪肝（NAFLD）
  • 其他疾病类型

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

  • 主要趋势
  • 影像学
  • 肝臟活检
  • 内视镜检查
  • 实验室测试

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

  • 主要趋势
  • 医院
  • 实验室
  • 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott Laboratories
  • BioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA Medical
  • Laboratory Corporation of America Holdings
  • Meril Life Sciences Pvt. Ltd.
  • Qiagen N.V.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 7939

Global Liver Disease Diagnostics Market is expected to register a CAGR of 7.3% between 2024-2032, fueled by technological advancements, rising prevalence of liver diseases, and increasing awareness about early diagnosis.

According to WHO, globally, 354 million individuals are affected by hepatitis B or C infections. Factors such as sedentary lifestyles, unhealthy dietary habits, and the prevalence of alcohol consumption are contributing to the rise in liver diseases, thereby increasing the demand for advanced diagnostic solutions. Moreover, the aging population, particularly in developed regions, is more susceptible to liver-related ailments. Additionally, the emphasis on early detection and intervention to prevent severe complications is fostering the adoption of liver disease diagnostic tests and procedures.

The overall liver disease diagnostics industry is classified based on disease type, technique, end-use, and region.

The liver cancer segment is poised to grow substantially till 2032, owing to the high mortality rate and limited treatment options, especially in advanced stages. Consequently, there is a pressing need for accurate and timely diagnosis of liver cancer. There are various diagnostic modalities such as imaging techniques (CT scan, MRI), blood tests (AFP, AFP-L3), and biopsy procedures. Continuous advancements in imaging technologies and biomarker identification are also enhancing the precision and reliability of liver cancer diagnosis, further propelling industry growth.

The endoscopy technique segment is anticipated to expand rapidly through 2032, offering direct visualization and tissue sampling capabilities. The evolution of endoscopic imaging technologies, including high-definition scopes and advanced imaging modalities such as narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), is revolutionizing liver disease diagnosis by providing detailed insights into tissue morphology and vascularity, propelling segment growth.

Europe liver disease diagnostics market will have lucrative opportunities during the forecast period, owing to factors such as the high prevalence of liver diseases, well-established healthcare infrastructure, and proactive government initiatives aimed at combating liver-related morbidity and mortality. The presence of key players and research institutions focused on liver health further augments the growth prospects in the region. Additionally, the rising geriatric population and increasing awareness about the importance of early diagnosis are driving the demand for liver disease diagnostic tests and procedures across Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increase in prevalence of liver diseases
      • 3.2.1.2 Rise in smoking, alcohol and drug consumption
      • 3.2.1.3 Technological advancements in diagnostic kits
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of diagnostic tests
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursemnt scenario
  • 3.6 Future market trends
  • 3.7 Technological landscape
  • 3.8 Porter's analysis
    • 3.8.1 Supplier power
    • 3.8.2 Buyer power
    • 3.8.3 Threat of new entrants
    • 3.8.4 Threat of substitutes
    • 3.8.5 Industry rivalry
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hepatitis
  • 5.3 Cirrhosis
  • 5.4 Liver cancer
  • 5.5 Non-alcoholic fatty liver disease (NAFLD)
  • 5.6 Other disease types

Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging
  • 6.3 Liver biopsy
  • 6.4 Endoscopy
  • 6.5 Laboratory tests

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Laboratories
  • 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 BioMerieux SA
  • 9.3 Bio-Rad Laboratories Inc.
  • 9.4 Cosara Diagnostics Pvt Ltd.
  • 9.5 F. Hoffmann-La Roche Ltd.
  • 9.6 HORIBA Medical
  • 9.7 Laboratory Corporation of America Holdings
  • 9.8 Meril Life Sciences Pvt. Ltd.
  • 9.9 Qiagen N.V.
  • 9.10 Siemens Healthcare GmbH
  • 9.11 Thermo Fisher Scientific Inc.